Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 5/20 | 0.35 |
| ▸ | RXRA | P19793 | 3/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 5/20 | 0.32 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.32 |
| ▸ | EGFR | P00533 | 2/20 | 0.31 |
| ▸ | BTK | Q06187 | 2/20 | 0.31 |
| ▸ | DRD1 | P21728 | 1/20 | 0.31 |
| ▸ | XIAP | P98170 | 1/20 | 0.30 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13721567 | 0.77 | RXRA (0.32) | RXRAGRIN1GRIN2B | |
| SCHEMBL17354628 | 0.77 | RXRA (0.40) | RXRAGRIN1GRIN2BDRD1 | |
| SCHEMBL12593967 | 0.75 | KDM4E (0.38) | RXRAGRIN1GRIN2BSCN9ASCN10A | |
| SCHEMBL30939671 | 0.73 | POLB (0.33) | MCHR1RXRAGRIN1GRIN2BDRD1 | |
| SCHEMBL22026376 | 0.73 | POLB (0.33) | MCHR1RXRAGRIN1GRIN2BDRD1 | |
| SCHEMBL1978645 | 0.73 | POLB (0.33) | MCHR1RXRAGRIN1GRIN2BDRD1 | |
| SCHEMBL30939555 | 0.72 | AR (0.45) | DRD1 | |
| SCHEMBL1982062 | 0.72 | AR (0.45) | DRD1 | |
| SCHEMBL19749082 | 0.71 | AR (0.41) | RXRAGRIN1GRIN2BDRD1 | |
| SCHEMBL19805321 | 0.71 | DRD1 (0.32) | SCN9ADRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160058737-A1 | IMIDAZOLIDINEDIONE DERIVATIVES | AUTIFONY THERAPEUTICS LIMITED (GB) | 2016-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160058737-A1 | IMIDAZOLIDINEDIONE DERIVATIVES | KCND3, KCNK3, KCNA3 | MCHR1 1923/4885RXRA 3878/4885GRIN1 180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.